Telix Pharmaceuticals Limited (TLPPF)
Stock analysis · OTC · Healthcare · Biotechnology
Telix Pharmaceuticals Limited (TLPPF) is a publicly traded company in the Healthcare sector. Trailing PE 97.75. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Proprietary Signals
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy ca…
Valuation
| P/E (TTM) | 97.75× |
|---|---|
| P/S (TTM) | 3.59× |
| P/B | 6.50× |
| P/FCF (TTM) | -54.31× |
| EV / EBITDA | 115.50× |
| EV / Sales | 3.96× |
| Earnings Yield | 1.03% |
| Free Cash Flow Yield | -1.84% |
Fundamentals
| Enterprise Value | $3.50B |
|---|---|
| Revenue (TTM) | $884.82M |
| Net Income (TTM) | $32.75M |
| Free Cash Flow (TTM) | -$44.61M |
| Net Debt | $327.81M |
| Working Capital | $245.57M |
| Gross Margin | 52.14% |
| Operating Margin | -0.78% |
| Net Margin | 3.69% |
| Return on Equity | 7.24% |
| Return on Invested Capital | -0.61% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap